Michael H. Kim, MD, MMM
Michael H. Kim, MD, MMM

Michael H. Kim, MD, MMM

Chair, Department of Medicine
School of Medicine, Omaha Campus


  • Cardiac Electrophysiology
  • Cardiovascular Disease

Academic Appointments


  • Medicine


  • Professor


Michael H. Kim, MD, MMM is a Professor of Medicine and Chair of the Department of Medicine.  He is a graduate of Princeton University, the University of Rochester School of Medicine and Dentistry, and Carnegie-Mellon University; all post-graduate medical training was at the University of Michigan.  He has served in leadership roles as Chief of Cardiology, Director of the Arrhythmia Service, Director of the Electrophysiology Laboratory, and as a Fellowship Director both in Electrophysiology and Cardiology.  Prior positions have been in institutions such as Northwestern University, The Alpert Medical School of Brown University, Rush University, and Washington University in St. Louis.  He is the author or co-author of 190 manuscripts and abstracts and serves on the Editorial Board of the Journal of the American College of Cardiology and serves as an Editorial referee for several other impact journals.  He is recognized for cardiovascular outcomes as it relates to arrhythmias and other electrophysiology-related areas.  He has been noted multiple times as a Castle-Connolly Top Doctor in Electrophysiology.

Publications and Presentations


  • Practical Insights into Anticoagulation for an Aging Population, Sr Care Pharm, 35, 150, 2020
  • Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation:  an analysis using Administrative Claims Data, Advances in Therapy, 35 (11), 1-122069-2080, 2018
  • Hospitalization and costs in primary prevention ICD recipients:  who determines the outcomes?, Journal of the American College of Cardiology:Clinical Electrophysiology, 4 (2), 254-256, 2018
  • Impact of warfarin on atrial fibrillation outcomes related to economic consumption patterns:  hospitalization, cost, and mortality may be predictable and modifiable at the population level, Advances in Therapy, 33 (9), 1579-1599, 2016
  • Patterns of dofetilide use for the treatment of atrial fibrillation, Journal of Innovations in Cardiac Rhythm Management, 7, 2425-2428, 2016
  • A call for appropriate evidence and outcomes-based use and measurement of anticoagulation for atrial fibrillation:  moving the population towards improved health via multiple stakeholders, Journal of Managed Care & Specialty Pharmacy, 21 (11), 1034-1038, 2015
  • A case series of anomalous high pacing lead impedances in normally functioning leads, Heart Rhythm Case Reports, 1 (6), 449-452, 2015
  • Time course of appropriate implantable cardioverter-defibrillator therapy and implications for guideline-based driving restrictions, Heart Rhythm, 12 (8), 1728-1736, 2015
  • Shared risk factors for anticoagulation in nonvalvular atrial fibrillation:  a dilemma in clinical decision making, Journal of the American College of Cardiology, 63 (20), 2148-2150, 2014
  • Health care burden of dyspepsia among nonvalvular atrial fibrillation patients, Journal of Managed Care Pharmacy, 20 (4), 391-399, 2014
  • Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter, Advances in Therapy, 31 (3), 318-332, 2014
  • Cardiac troponin assessment following atrial fibrillation ablation: implications for chest pain evaluation, International Journal of Clinical Cardiology, 1 (2), 2014
  • The relationship between defibrillation threshold and total mortality, Journal of Interventional Cardiac Electrophysiology, 38 (3), 203-208, 2013
  • Prospective evaluation of cinefluoroscopy and chest radiography for Riata lead defects: implications for future lead screening, Journal of Interventional Cardiac Electrophysiology, 38 (2), 131-135, 2013
  • Effectiveness of VF induction with DC Fibber versus conventional induction methods in patients on chronic amiodarone therapy, Journal of Interventional Cardiac Electrophysiology, 38 (2), 137-141, 2013
  • Device advisory letters:  readability and comprehension, patient-centered outcomes not to be "misunderstood", Heart Rhythm, 10 (4), 508-509, 2013
  • Treatment targets in atrial fibrillation:  "is feeling better good enough?", Journal of the American College of Cardiology, 61, 461-462, 2013
  • Prevalence and predictors of cable extrusion and loss of electrical integrity with the Riata defibrillator lead, Journal of Cardiovascular Electrophysiology, 23 (11), 1207-1212, 2012
  • Catheter ablation of atrial fibrillation in Octogenarians:  the Right "medicine?", Journal of Cardiovascular Electrophysiology, 23 (7), 694-696, 2012
  • Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation, Expert Review of Clinical Pharmacology, 5 (2), 163-171, 2012
  • Concepts in disease progression of atrial fibrillation and implications for medical management, Journal of Innovations in Cardiac Rhythm Management, 3, 697-712, 2012
  • Long-term insertable loop monitors:  how much should we watch to get an answer (diagnosis)?, Journal of Cardiovascular Electrophysiology, 23 (1), 72-73, 2012
  • One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis, Clinical Therapeutics, 33 (11), 1668-1681, 2011
  • Estimation of total incremental health care costs in patients with atrial fibrillation in the United States, Circulation: Cardiovascular Quality and Outcomes, 4 (3), 313-320, 2011
  • A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy, Heart Rhythm, 8 (5), 685-691, 2011
  • Predicting the risk of heart failure events and subsequent mortality:  what doth the seer know?, Journal of Cardiovascular Electrophysiology, 21 (11), 1224-1225, 2010
  • Total costs and atrial fibrillation ablation success or failure in Medicare-aged patients in the United States, Advances in Therapy, 27 (9), 600-612, 2010
  • The impact of stored atrial rhythm diagnostics in permanent pacemakers and the management of atrial fibrillation:  the Vitatron Selection AFm Registry Study, Journal of Interventional Cardiac Electrophysiology, 28 (3), 227-234, 2010
  • Predictors of early mortality in patients age 80 and older receiving implantable defibrillators, Pacing and Clinical Electrophysiology, 33 (8), 981-987, 2010
  • Patterns and predictors of discontinuation of rhythm control drug therapy in patients with newly diagnosed atrial fibrillation, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 29 (12), 1417-1426, 2009
  • Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy, Current Medical Research and Opinion, 25 (12), 3037-3047, 2009
  • Cost of atrial fibrillation in United States managed care organizations, Advances in Therapy, 26 (9), 847, 2009
  • Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy, Journal of Cardiovascular Electrophysiology, 20 (8), 894-900, 2009
  • National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US, Advances in Therapy, 26 (8), 784-794, 2009
  • A novel method for sinus node modification and phrenic nerve protection in resistant cases, Journal of Cardiovascular Electrophysiology, 20 (6), 689-691, 2009
  • Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation, Current Medical Research and Opinion, 25 (5), 1215-1220, 2009
  • Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation, Annals of Pharmacotherapy, 43 (5), 840-848, 2009
  • Influence of structural heart disease on characteristics of atrial fibrillation recurrence in patients with dual chamber pacemakers, Journal of Electrocardiology, 42 (2), 128-135, 2009
  • A written policy increases compliance with guidelines for therapeutic anticoagulation prior to elective direct current cardioversion of atrial fibrillation, Journal of cardiovascular nursing, 22 (5), 417-421, 2007
  • A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy, Journal of Cardiovascular Electrophysiology, 18 (5), 490-496, 2007
  • Value of pacemaker atrial diagnostic data in patients with paroxysmal atrial fibrillation:  an opportunity to improve rates of warfarin utilization, Pacing and Clinical Electrophysiology, 30 (4), 580-583, 2007
  • Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air polllutants in the St. Louis, Missouri metropolitan area, Occupational and Environmental Medicine, 63 (9), 591-596, 2006
  • Left bundle branch block during orthodromic reciprocating tachycardia:  where is the accessory pathway?, Heart Rhythm, 3 (5), 610-611, 2006
  • Cardiac resynchronization therapy:  a potential option for congenitally corrected transposition of the great vessels, Journal of Heart and Lung Transplantation, 24 (12), 2293-2296, 2005
  • Polymorphic ventricular tachycardia with a normal QT interval following azithromycin, Pacing and Clinical Electrophysiology, 28 (11), 1221-1222, 2005
  • Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery:  a meta-analysis, Annals of Internal Medicine, 143 (5), 327-336, 2005
  • Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study, Archives of Internal Medicine, 165 (10), 1185-1191, 2005
  • Cardiac pacing:  the state of the art, The Lancet, 364, 1701-1719, 2004
  • Low molecular weight heparin in atrial fibrillation management:  facts, fiction, future, Cardiac Electrophysiology Review, 7 (4), 397-400, 2003
  • Diagnostic value of single versus dual chamber electrograms recorded from an implantable defibrillator, Journal of Interventional Cardiac Electrophysiology, 9 (1), 49-53, 2003
  • Maintenance of sinus rhythm in patients with atrial fibrillation:  an AFFIRM substudy of the first antiarrhythmic drug., Journal of the American College of Cardiology, 42 (1), 20-29, 2003
  • Use patterns of low molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation, American Heart Journal, 145 (4), 665-669, 2003
  • A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low molecular weight heparin, Annals of Emergency Medicine, 40 (2), 187-192, 2002
  • The immediate reproducibility of T wave alternans during bicycle exercise, Pacing and Clinical Electrophysiology, 25 (8), 1185-1191, 2002
  • Effect of amiodarone +/- diltiazem +/- beta-blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting, American Journal of Cardiology, 89 (9), 1126-1128, 2002
  • Atrial fibrillation after coronary surgery:  comparison between different health care systems, International Journal of Cardiology, 82 (3), 209-218, 2002
  • Kearns-Sayre Syndrome:  association with Long QT syndrome?, Journal of Cardiovascular Electrophysiology, 13 (2), 184-185, 2002
  • Importance of limiting atrial fibrillation after heart surgery, Cardiology Review, 19 (1), 19-23, 2002
  • Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter, American Journal of Cardiology, 88 (12), 1428-1431, 2001
  • Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room, American Journal of Cardiology, 88 (1), 74-76, 2001
  • Prevalence of central venous occlusion in patients with chronic defibrillator leads, American Heart Journal, 141 (5), 813-816, 2001
  • Postoperative atrial fibrillation after heart surgery:  what are the goals of prevention?, American Heart Journal, 141 (5), 691-693, 2001
  • Effect of postoperative atrial fibrillation on length of stay after cardiac surgery (the postoperative atrial fibrillation in cardiac surgery study (PACS2), American Journal of Cardiology, 87 (7), 881-885, 2001
  • Electrogram polarity and cavotricuspid isthmus block during ablation of typical atrial flutter, Journal of Cardiovascular Electrophysiology, 12 (4), 393-399, 2001
  • Cardiac risk assessment in noncardiac thoracic surgery, International Journal of Cardiology, 13 (2), 137-146, 2001
  • Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation, American Journal of Cardiology, 87 (5), 649-651, 2001
  • Diastolic dysfunction in the presence of left ventricular systolic dysfunction: implications of beta-adrenergic blocking therapy, Congestive Heart Failure, 7 (2), 71-76, 2001
  • Pharmacologic and nonpharmacologic approaches to the prevention of atrial fibrillation after heart surgery, Cardiovascular Reviews and Reports, 22 (5), 292-296, 2001
  • Cost analysis of transthoracic cardioversion of atrial fibrillation with and without ibutilide pretreatment, Journal of Cardiovascular Pharmacology and Therapeutics, 5 (4), 259-266, 2000
  • Effects of digoxin on acute, atrial fibrillaton-induced changes in atrial refractoriness, Circulation, 102 (20), 2503-2508, 2000
  • Diagnostic value of tachycardia features and pacing maneuvers during paroxsymal supraventricular tachycardia, Journal of the American College of Cardiology, 36 (2), 574-582, 2000
  • Effect of chronic amiodarone therapy on defibrillation energy requirements in humans, Journal of Cardiovascular Electrophysiology, 11 (7), 736-740, 2000
  • Prevalence and significance of exit block during arrhythmias arising in pulmonary veins, Journal of Cardiovascular Electrophysiology, 11 (4), 379-386, 2000
  • Comparison of endocardial activation times at effective and ineffective ablation sites within pulmonary veins, Journal of Cardiovascular Electrophysiology, 11 (2), 155-159, 2000
  • Outcome of men with ischemic cardiomyopathy, asymptomatic nonsustained ventricular tachycardia, and negative electrophysiology studies, American Journal of Cardiology, 85 (1), 119-121, 2000
  • Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract, American Journal of Cardiology, 84 (10), 1266-1268, 1999
  • Bayesian persuasion, Circulation, 100 (16), e68-e72, 1999
  • Effects of beta-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy, Circulation, 100 (7), 729-735, 1999
  • Effect of electrode polarity on the energy required for transthoracic atrial defibrillation, American Journal of Cardiology, 84 (2), 228-230, 1999
  • Target temperatures of 48 degrees celsius versus 60 degrees celsius during slow pathway ablation:  a randomized comparison, Journal of Cardiovascular Electrophysiology, 10 (6), 799-803, 1999
  • Sudden death in a 55-year-old woman with systemic lupus erythematosus, Circulation, 98 (3), 271-275, 1998
  • Silent ischemic cardiomyopathy and left coronary ostial stenosis secondary to radiation therapy, Clinical Cardiology, 19 (7), 602, 1996


  • , Circulation: Cardiovascular Quality and Outcomes, 13, A341, 2020
  • Delayed versus Early Cardioversion for Patients with Uncomplicated Atrial Fibrillation Meta-Analysis, J Am Coll Cardiol, 75 (11), 420, 2020
  •  Kim SY, Kim KM, Kim MH.  National economic cost burden of atrial flutter only patients without atrial fibrillation.  , J American College of Cardiology, 73 (Supplement 1), 329, 2019
  • Kim KM, Kim SY, Kim MH.  Comparative variation in health care resource utilization between patients with atrial flutter only versus atrial fibrillation with or without atrial flutter. , J Am Coll Cardiol, 73 (Supplement 1), 332, 2019


  • Andukuri V, Xu L, Puckrein GA, Walters RW, Kim MH.  Population-level insights into 30-day mortality in Medicare beneficiaries after inpatient and outpatient catheter ablation for atrial fibrillation.  Virtual Abstract Poster Session at AHA Quality of Care and Outcomes Scientific Sessions., 2020
  • American College of Cardiology Scientific Sessions Poster Presentation (Virtual): Delayed versus Early Cardioversion for Patients with Uncomplicated Atrial Fibrillation Meta-Analysis, 2020
  • Internal Medicine Grand Rounds:  Do We Really Know Atrial Flutter: Clinical and Epidemiological Perspectives, 2020
  • American College of Cardiology Scientific Sessions Abstract Presentation (Poster): National Economic Cost Burden of Atrial Flutter Only Patients Without Atrial Fibrillation; New Orleans, LA, 2019
  • American College of Cardiology Scientific Sessions Abstract Presentation (Poster): Comparative Variation in Health Care Resource Utilization Between Patients With Atrial Flutter Only Versus Atrial Fibrillation With Or Without Atrial Flutter; New Orleans, LA, 2019
  • Invited Lecture:  Cardiovascular Outcomes and Atrial Fibrillation; Maricopa Medical Center; Phoenix, AZ, 2019

Research and Scholarship

Research and Scholarship Interests

  • Cardiovascular Outcomes and Arrhythmias; atrial fibrillation; stroke; ICD therapy; health care disparities; anticoagulation

Current Research Projects

  • Disparities in care related to atrial fibrillation and anticoagulation; atrial arrhythmias and economic cost burden

Awards and Honors

  • Ablation devices and related methods thereof (patent app 13/060,632), 2011
  • Cardiac pacing lead and delivery sheath (patent app 12/620,185), 2010
  • Systems and methods for catheter stability (patent app 12/620,178), 2010
  • Elite/Top Reviewer Award: 2014, 2015, and 2016, Journal of the American College of Cardiology, 2014
  • Remarkable Reviewer Award 2017, Heart Rhythm Journal, 2017
  • Top Grade/Best Reviewers Designation, 2012, Annals of Internal Medicine, 2012
  • NASPE Traveling Fellowship, North American Society of Pacing and Electrophysiology, 1998
  • Midwest Trainee Investigator Award, Central Society for Clinical Research, 1994
  • Remarkable Reviewer Award 2018, Heart Rhythm Journal, 2019